Welcome to our dedicated page for Nuvalent news (Ticker: NUVL), a resource for investors and traders seeking the latest updates and insights on Nuvalent stock.
Nuvalent, Inc. develops precisely targeted small-molecule therapies for clinically proven kinase targets in cancer. Its news centers on investigational programs including zidesamtinib for ROS1-positive NSCLC, neladalkib for ALK-positive NSCLC, and HER2-altered NSCLC research, with updates on clinical data from ARROS-1 and ALKOVE-1, FDA submission activity, companion-diagnostic collaborations, and discovery-stage programs.
Company updates also cover quarterly financial results, research and development spending, cash resources, commercial-readiness activities for potential oncology launches, medical-meeting presentations, and leadership or governance developments tied to its clinical-stage biopharmaceutical model.
Nuvalent, Inc. (Nasdaq: NUVL) announced the closing of an upsized underwritten public offering of 7,895,522 shares of Class A common stock at $33.50 per share, generating gross proceeds of approximately $264.5 million. This includes 1,029,850 shares from the full exercise of underwriters' options. The shares were offered under a shelf registration statement effective since August 16, 2022. Notably, J.P. Morgan, Cowen, Piper Sandler, and BMO Capital Markets acted as joint book-running managers for this transaction.
Nuvalent, Inc. (Nasdaq: NUVL) has priced its underwritten public offering of 6,865,672 shares of Class A common stock at $33.50 per share, aiming for gross proceeds of approximately $230 million before expenses. The offering is expected to close on November 3, 2022, pending customary conditions. There is also a 30-day option for underwriters to buy an additional 1,029,850 shares. This offering is part of a shelf registration statement effective since August 16, 2022.
Nuvalent, Inc. (Nasdaq: NUVL) has launched an underwritten public offering of $200 million of Class A common stock, all offered by the company. A 30-day underwriters' option for an additional 15% of shares is also expected. The offering is subject to market conditions, and completion is uncertain. The offering is conducted under a shelf registration statement effective since August 16, 2022. Nuvalent specializes in targeted cancer therapies, focusing on kinase targets. J.P. Morgan and others are managing the offering.
Nuvalent reported preliminary Phase 1 data for NVL-520, a novel ROS1-selective inhibitor, at the EORTC-NCI-AACR Symposium. The treatment showed a favorable safety profile, with no dose-limiting toxicities or serious adverse events observed among 35 enrolled patients. Encouraging signs of efficacy were noted, with 48% of heavily pre-treated ROS1-positive NSCLC patients achieving partial responses. Notable response rates were 78% in patients with G2032R mutations and 73% in those with CNS metastases. NVL-520 aims to address challenges associated with existing treatments, including resistance mutations and CNS adverse effects.
Nuvalent, Inc. (Nasdaq: NUVL) announced new preclinical data for its selective kinase inhibitors NVL-330 and NVL-655 at the 34th EORTC-NCI-AACR symposium. NVL-330 targets HER2 exon 20 insertion mutations and demonstrates selectivity over wild-type EGFR, along with potential for treating brain metastases. Preclinical results indicate NVL-655's activity in ALK-positive tumors, overcoming resistance mutations. Nuvalent continues to advance its pipeline, showcasing significant therapeutic potential against hard-to-treat cancers.
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, will host a live webcast and conference call on October 28, 2022, at 8:30 a.m. EDT, to discuss preliminary Phase 1 data from the ARROS-1 clinical trial of NVL-520, alongside additional preclinical updates. This event coincides with the 34th EORTC-NCI-AACR Symposium in Barcelona, Spain. Interested parties can access the webcast via Nuvalent’s investor page or by phone using the provided dial-in details.
On October 6, 2022, Nuvalent, Inc. (Nasdaq: NUVL) appointed Dr. Michael L. Meyers, an experienced oncologist and drug developer, to its Board of Directors. Dr. Meyers has been a Senior Clinical Advisor to Nuvalent since 2020 and brings a wealth of experience from his roles at Syndax Pharmaceuticals and Johnson & Johnson. His expertise is expected to enhance Nuvalent's capabilities as it advances its clinical programs, including NVL-520 and NVL-655, which target advanced ROS1-positive and ALK-positive non-small cell lung cancer. The company continues to position itself as a leader in oncology therapies.
Nuvalent, Inc. (Nasdaq: NUVL) announced it will present preliminary results from the ARROS-1 Phase 1/2 trial of NVL-520, aimed at treating advanced ROS1-positive non-small cell lung cancer (NSCLC), during the EORTC-NCI-AACR Symposium from October 26-28, 2022. Additional presentations will feature new preclinical data on NVL-655, an ALK-selective inhibitor, and the selection of NVL-330, targeting HER2 exon 20 insertion-positive tumors. The conference call is scheduled for October 28, 2022, to discuss these developments further.
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, announced CEO James Porter will participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference on September 8, 2022, at 2:35 p.m. ET in Boston. Nuvalent focuses on developing targeted therapies for cancer, leveraging expertise in chemistry and drug design to combat resistance and minimize adverse effects. A live webcast of the event will be accessible on their website, with an archive available for 30 days.
Nuvalent, Inc. (Nasdaq: NUVL) announced significant pipeline progress in its press release dated August 10, 2022. The company plans to release preliminary dose escalation data from the ARROS-1 trial for NVL-520 in advanced ROS1-positive NSCLC in the second half of 2022. Nuvalent is also actively dosing patients in the ALKOVE-1 trial for NVL-655, targeting advanced ALK-positive NSCLC. Financially, as of June 30, 2022, Nuvalent had cash reserves of $257 million, with R&D expenses at $13.6 million and a net loss of $18.5 million for Q2 2022.